F-1: Mainz Biomed Launches Public Offering to Fund Advanced Cancer Diagnostic Development Amidst Continued Losses

Mainz Biomed N.V. is undertaking a best-efforts public offering of up to 1,470,588 ordinary and pre-funded units to raise approximately $2.565 million net, aiming to advance its colorectal and pancreatic cancer screening tests despite ongoing operating losses and significant shareholder dilution.

Summary

• Mainz Biomed N.V. is offering up to 1,470,588 ordinary units, each comprising one ordinary share and 1.5 warrants, at an assumed price of $2.04 per unit.
• Pre-funded units are also offered for purchasers whose beneficial ownership would exceed 4.99% (or 9.99% at election), consisting of one pre-funded warrant and 1.5 warrants, priced at $0.0001 less than ordinary units.
• The pre-funded warrants are immediately exercisable at $0.0001 per share, while the ordinary warrants are immediately exercisable at $2.04 per share and expire on the fifth anniversary of issuance.
• The company expects to receive net proceeds of approximately $2,565,000 from this best-efforts offering, after deducting placement agent fees and estimated offering expenses of $435,000.
• Proceeds are intended for the eAArly DETECT 2 study, development of next-generation screening products (colorectal and pancreatic cancer), commercial expansion of ColoAlert, debt repayment, and general corporate purposes.
• Mainz Biomed reported a net loss of $21,650,663 for the year ended December 31, 2024, and $26,295,727 for the year ended December 31, 2023.
• The company had a working capital deficit of $1,894,484 as of December 31, 2024, compared to a deficit of $257,040 as of December 31, 2023.
• A 1:40 reverse stock split was effectuated on December 3, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• The company has restructured operations, including a 65% reduction in personnel and decreased external consulting expenses, to focus on its core diagnostic business.
• Clinical studies for the next-generation mRNA-based CRC screening test (ColoFuture and eAArly DETECT) showed high sensitivity and specificity for colorectal cancer (92% sensitivity, 90% specificity in pooled data) and advanced adenomas (82% sensitivity, 90% specificity in pooled data).

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including substantial operating losses and a working capital deficit, and the current capital raise is a 'best-efforts' offering with no minimum, indicating high funding risk. While product development shows promising clinical results, the financial instability and potential for further dilution outweigh these positives for immediate investment sentiment.

Positives

• Next-generation mRNA-based CRC screening test demonstrated strong clinical performance with pooled study results showing 92% sensitivity for CRC and 90% specificity, and 82% sensitivity for advanced adenomas with 90% specificity.
• Collaboration agreement with Thermo Fisher Scientific Inc. provides development resources, instrumentation, and consumables at significant discounts for mRNA-based assay development.
• Partnership with Quest Diagnostics for clinical trial laboratory services for the ReconAAsense study, with an option for Quest to exercise semi-exclusive testing rights upon FDA approval.
• Acquired an exclusive license from Liquid Bioscience, Inc. for novel mRNA biomarkers for non-invasive pancreatic cancer detection via a blood test, with an option to acquire them.
• Strategic realignment and cost reduction measures, including a 65% reduction in personnel, aim to position the business for future success.

Negatives

• The company is an early revenue stage company and has incurred significant operating losses since inception, with a net loss of $21,650,663 in 2024.
• The offering is on a 'best efforts' basis with no minimum amount of securities required to be sold, which may result in insufficient capital raised to fund business plans.
• Investors will experience immediate and substantial dilution of $1.05 per ordinary share (approximately 52%) as a result of this offering.
• The company has a working capital deficit of $1,894,484 as of December 31, 2024, indicating short-term liquidity challenges.
• The market price of ordinary shares has been volatile, and further reverse stock splits may be necessary to maintain Nasdaq listing, which could negatively impact investor perception.
• No public market exists for the pre-funded warrants or the ordinary share purchase warrants being offered, limiting their liquidity.

Risks

• Inability to attain profitability due to being an early revenue stage company with a history of operating losses.
• Terms of subsequent financings may adversely impact investment due to potential dilution or unfavorable terms.
• Inability to manage growth effectively could harm the business.
• Substantial dependence on management, posing a risk if key personnel depart.
• Difficulties protecting interests and limited ability to protect rights through U.S. federal courts due to Dutch incorporation and substantial assets/management outside the U.S.
• Failure to generate sufficient revenue from client or laboratory partnerships to achieve and maintain profitability.
• Success heavily depends on ColoAlert screening tests, and sales could be impacted by physician reluctance or competing tests.
• Failure to establish, maintain, and strengthen ColoAlert and other brands could adversely affect product acceptance.
• May decide not to incorporate certain biomarkers after additional studies, impacting product development.
• Potential technology transfer challenges and expenses in adding new tests or expanding geographically.
• Dependence on future collaborations for diagnostic test development, commercialization, manufacturing, regulatory compliance, sales, marketing, and distribution.
• Inability to obtain and enforce patents or protect trade secrets could lead to competition and pricing pressures.
• Results of FDA required studies may not create desired clinical performance, delaying product launch in the U.S.
• Global operations expose the company to numerous and conflicting legal and regulatory requirements, with potential for significant fines and penalties for violations.
• Need to maintain facilities or relationships with third-party laboratories for manufacturing and use of diagnostic tests, with risks if these facilities are harmed or inoperable.
• Anticipated requirement to obtain regulatory approval for diagnostic test products to enter new markets.
• Volatility in the market price of ordinary shares, which may be disproportionate to operating performance.
• Potential for further dilution if additional ordinary shares or preferred shares are issued.
• No intention to pay dividends, limiting ways for investors to gain on their investment.
• FINRA sales practice requirements may limit ability to buy and sell ordinary shares, depressing prices.
• Volatility in share price may subject the company to securities litigation.
• Risk of delisting from Nasdaq if continued listing requirements are not met, affecting liquidity and trading price.
• Broad discretion in the use of net proceeds from the offering, which may not be used effectively.
• Potential for privately negotiated warrant inducements with prior warrant holders, affecting stock price and causing substantial dilution.
• Loss of foreign private issuer status in the future could result in significant additional cost and expense due to increased U.S. regulatory requirements.
• Changes to United States tariff and import/export regulations could negatively affect business.
• Changes in U.S. government policies, including reductions in federal research funding and cuts to regulatory review staff at the FDA, could adversely affect the business.

Future Outlook

The company anticipates releasing an interim readout on the eAArly DETECT 2 study results towards the end of summer 2025, once approximately 50% of proposed clinical subjects have been tested. The next-generation test is poised for inclusion in statutory reimbursement schemes in Europe due to its enhanced sensitivity and specificity for detecting early-stage colorectal cancer and advanced adenomas.

Management Comments

• Management believes the implemented cost reductions will position the business for success in 2025 and beyond.
• Management anticipates retaining all future earnings and other cash resources for the future operation and development of the business, and does not intend to pay any dividends for the foreseeable future.

Industry Context

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer death globally, with the annual market for CRC diagnostics anticipated to surpass $30 billion by 2032. There is a growing trend to lower the recommended starting age for CRC screening, with the U.S. FDA recently recommending age 45. Pancreatic cancer is one of the most lethal malignancies due to asymptomatic early stages, highlighting an urgent need for enhanced early diagnostic methods.

Comparison to Industry Standards

• The company's next-generation mRNA CRC screening test, combining UdeS Biomarkers with FIT tests and an AI/machine learning algorithm, demonstrated a pooled sensitivity of 92% for CRC and 90% specificity, along with 82% sensitivity for advanced adenomas and 90% specificity across 690 clinical subjects in Europe and the U.S.
• This performance is presented as highly effective in detecting CRC lesions, including advanced precancerous lesions, compared to general diagnostic tests, with the Journal of the National Cancer Institute reporting in 2022 that diagnostic tests with 10% sensitivity for advanced adenomas could reduce mortality by 47%, and 76% sensitivity could reduce mortality by 67% for adults over 45.

Corporate Governance

Legal Proceedings

• Filed a lawsuit against an investment bank in 2024 in the New York State Supreme Court regarding rights and obligations under relevant contracts related to the 2021 IPO.
• The investment bank initiated arbitration proceedings with FINRA, which were formally stayed on September 13, 2024, pending the court's determination of the proper venue for the dispute.
• The company intends to vigorously defend against all claims, but the outcome and potential loss cannot be predicted at this preliminary stage.

Stakeholder Impact

• Shareholders face immediate and substantial dilution from the offering (approximately 52% or $1.05 per share).
• Existing shareholders may experience further dilution from the exercise of outstanding warrants and options, and conversion of convertible debt.
• Shareholders will not receive dividends in the foreseeable future, as the company intends to retain earnings for business development.
• Employees have been significantly impacted by a 65% reduction in personnel as part of cost reduction measures.
• Investors are exposed to a high degree of risk due to the company's early revenue stage, history of operating losses, and the 'best efforts' nature of the offering.

Next Steps

• Release an interim readout on the eAArly DETECT 2 study results towards the end of summer 2025.
• Conduct the eAArly DETECT 2 study and the pivotal FDA PMA study (reconAAsense) for the next-generation CRC screening product.
• Continue development of the next-generation colorectal cancer screening product and the PancAlert product candidate.
• Expand commercial presence of ColoAlert in Germany by building new laboratory partnerships and increasing product visibility.
• Progressively extend operations to additional European markets accustomed to personal health expenditures for ColoAlert.
• Pursue statutory reimbursement for the next-generation product in Germany and other regions.
• Validate ColoAlert for additional real-time PCR instruments used in laboratories worldwide.
• Continue research and development for PancAlert, including selecting and validating biomarker panels and optimizing detection technology.
• Assess requirements to certify the ColoAlert PCR kit under the new EU In-Vitro Diagnostics Regulation (IVD-R).

Key Dates

Recommendation

The company is in a precarious financial position, marked by significant operating losses and a working capital deficit, and the current 'best efforts' capital raise introduces considerable funding uncertainty. This financial instability and the substantial dilution for existing shareholders are major concerns. However, the company's product pipeline, particularly the next-generation colorectal cancer screening test, has demonstrated promising clinical results (high sensitivity and specificity), and strategic partnerships with major industry players like Thermo Fisher and Quest Diagnostics offer potential for future growth and market penetration. The long-term outlook hinges on successful product commercialization and achieving profitability, which remains highly speculative. Given the high risk but also the potential upside from its innovative diagnostic products, a 'Hold' recommendation is appropriate for investors willing to tolerate significant risk and monitor developments closely, rather than a 'Sell' which would disregard the promising pipeline.

Keywords

Cancer Diagnostics, Colorectal Cancer Screening, Pancreatic Cancer Detection, IVD Tests, mRNA Biomarkers, ColoAlert, PancAlert, eAArly DETECT, ReconAAsense, Public Offering, Warrants, Nasdaq, Biotechnology, Medical Devices, Clinical Trials, SEC Filing, Dilution, Financial Health